Nuvalent (NASDAQ:NUVL) Price Target Raised to $155.00

Nuvalent (NASDAQ:NUVL) had its target price hoisted by HC Wainwright from $130.00 to $155.00 in a research report report published on Monday morning, Marketbeat.com reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Nuvalent’s Q2 2026 earnings at ($1.48) EPS, Q3 2026 earnings at ($1.43) EPS, Q4 2026 earnings at ($1.19) EPS and FY2026 earnings at ($5.62) EPS.

Other research analysts also recently issued reports about the stock. Guggenheim began coverage on shares of Nuvalent in a research report on Thursday, September 4th. They set a “buy” rating and a $122.00 target price for the company. Canaccord Genuity Group began coverage on Nuvalent in a research note on Wednesday, November 12th. They set a “buy” rating and a $126.00 price objective for the company. UBS Group upped their target price on Nuvalent from $114.00 to $132.00 and gave the stock a “buy” rating in a research note on Friday, October 31st. Stifel Nicolaus initiated coverage on Nuvalent in a research report on Thursday, October 16th. They set a “buy” rating and a $115.00 price target for the company. Finally, Piper Sandler boosted their price target on Nuvalent from $112.00 to $128.00 and gave the company an “overweight” rating in a report on Monday, October 27th. Thirteen equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $137.69.

Nuvalent Trading Up 2.8%

Shares of NASDAQ:NUVL opened at $107.13 on Monday. Nuvalent has a twelve month low of $55.53 and a twelve month high of $112.53. The company’s 50 day moving average is $89.68 and its 200 day moving average is $81.43. The company has a market cap of $7.79 billion, a PE ratio of -20.14 and a beta of 1.31.

Nuvalent (NASDAQ:NUVL) last announced its quarterly earnings data on Thursday, October 30th. The company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.39) by ($0.31). During the same quarter last year, the business posted ($1.28) EPS. Equities research analysts predict that Nuvalent will post -3.86 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Nuvalent news, Director Matthew Shair sold 32,455 shares of the stock in a transaction that occurred on Tuesday, October 28th. The stock was sold at an average price of $100.27, for a total transaction of $3,254,262.85. Following the transaction, the director owned 1,383,044 shares in the company, valued at approximately $138,677,821.88. This represents a 2.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Alexandra Balcom sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, October 13th. The shares were sold at an average price of $88.51, for a total value of $1,770,200.00. Following the completion of the sale, the chief financial officer owned 61,734 shares of the company’s stock, valued at $5,464,076.34. This trade represents a 24.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 291,000 shares of company stock worth $27,207,121. 10.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On Nuvalent

Large investors have recently added to or reduced their stakes in the stock. CWM LLC lifted its holdings in Nuvalent by 588.5% during the first quarter. CWM LLC now owns 420 shares of the company’s stock valued at $30,000 after purchasing an additional 359 shares in the last quarter. ANTIPODES PARTNERS Ltd acquired a new position in shares of Nuvalent during the 1st quarter worth about $38,000. Aster Capital Management DIFC Ltd purchased a new position in Nuvalent in the 3rd quarter valued at about $38,000. Eastern Bank purchased a new position in Nuvalent in the 3rd quarter valued at about $52,000. Finally, Covestor Ltd boosted its holdings in Nuvalent by 705.7% in the 1st quarter. Covestor Ltd now owns 983 shares of the company’s stock worth $70,000 after buying an additional 861 shares during the last quarter. 97.26% of the stock is currently owned by institutional investors and hedge funds.

Nuvalent Company Profile

Nuvalent, Inc, a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.